Ginkgo Bioworks Holdings is the subject of a $17,750,000 securities class action settlement, known as the Ginkgo Securities Litigation, targeting investors who purchased shares through the 2021 Proxy/Registration Statement or on the open market between May 11, 2021 and October 5, 2021. The settlement fund totals $17,750,000, with a recovery of approximately $0.10 per share before deductions. The verified claim deadline was November 21, 2024 — this record preserves the official settlement terms and claim requirements for affected shareholders.